Market Research Logo

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2015

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2015’, provides an overview of the Adrenocortical Carcinoma (Adrenal Cortex Cancer)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Adrenocortical Carcinoma (Adrenal Cortex Cancer)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Overview
Therapeutics Development
Pipeline Products for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Overview
Pipeline Products for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Comparative Analysis
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics under Development by Companies
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics under Investigation by Universities/Institutes
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Products under Development by Companies
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Products under Investigation by Universities/Institutes
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Companies Involved in Therapeutics Development
Arbutus Biopharma Corporation
ArQule, Inc.
EnGeneIC Ltd
Marathon Pharmaceuticals, LLC
Merck KGaA
Orphagen Pharmaceuticals, Inc.
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ARQ-087 - Drug Profile Product Description
Mechanism of Action
R&D Progress
ATR-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
avelumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody Conjugate to Target B7-H3 for Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MP-110 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TargomiRs - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TKM-PLK1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Recent Pipeline Updates
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Product Development Milestones
Featured News & Press Releases
Mar 03, 2015: Atterocor Announces Data Presentations at ENDO 2015
Dec 31, 2014: Tekmira Provides Update on TKM-PLK1 Phase I/II Clinical Study in Patients With Advanced Gastrointestinal Neuroendocrine Tumors and Adrenocortical Carcinoma
Dec 11, 2014: Atterocor Expands Phase 1 Trial of ATR-101 to Additional Leading Adrenal Cancer Centers
Oct 15, 2013: Atterocor Announces Initiation of Phase 1 Clinical Trial of ATR-101 in Adrenocortical Carcinoma
Oct 08, 2013: Tekmira Provides Corporate Update On Oncology Product Candidate TKM-PLK1
Aug 12, 2013: Tekmira commences Phase I/II study of TKM-PLK1
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H2 2015
Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Arbutus Biopharma Corporation, H2 2015
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by ArQule, Inc., H2 2015
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by EnGeneIC Ltd, H2 2015
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Marathon Pharmaceuticals, LLC, H2 2015
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Merck KGaA, H2 2015
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics - Recent Pipeline Updates, H2 2015
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects, H2 2015
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H2 2015
Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Targets, H2 2015
Number of Products by Stage and Targets, H2 2015
Number of Products by Mechanism of Actions, H2 2015
Number of Products by Stage and Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report